Physician profile
Melissa A Cooley
NPI 1851501670
$2,292.76
in general payments reported to CMS, 2019-2025
25 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $129 · 2021: $125 · 2022: $375 · 2023: $211 · 2024: $299 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $719.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $341.55 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Pfizer INC. | $284.28 | 2019-2025 | |
| Welch Allyn | $99.98 | 2020 | |
| Astellas Pharma US INC | $84.20 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $82.63 | 2021-2025 | |
| Heartflow, INC. | $81.80 | 2025 | |
| Dexcom, INC. | $74.29 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $70.46 | 2022 | |
| Sequel Med Tech, LLC | $58.77 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $51.42 | 2019-2021 | |
| Medtronic, INC. | $49.88 | 2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $48.81 | 2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $42.47 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.31 | 2021-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.78 | 2019 | |
| Abbott Laboratories | $23.14 | 2025 | Eterna |
| Phathom Pharmaceuticals, INC. | $18.60 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $18.58 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $16.77 | 2025 | |
| Corcept Therapeutics | $15.64 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $15.44 | 2022 | |
| Daiichi Sankyo INC. | $12.98 | 2022 | |
| Lundbeck LLC | $12.82 | 2022 | |
| Amgen INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.